Skip to main content
Caplight Logo









CDI Labs

CDI Labs

Private
Mayagüez, Puerto RicoHealthcare & Life Scienceshttps://www.cdilabs.com/

Last Round

VC Round

Jan 9, 2023

Total Funding Raised

$7.1M

Company Overview

CDI Labs is a biotechnology company that provides specialized contract research and lab services for proteomics, including autoantibody biomarker discovery and target identification.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

proteomicscontract research organizationCRObiomarker discoveryantibody developmentautoantibody profilingphage displayprotein microarraydrug discovery servicesPhIP-Seqmonoclonal antibodiessynthetic biologylab-as-a-servicebiotech servicesprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CDI Labs Comparables

Compare CDI Labs with similar companies based on industry and business-model similarity.

CDI Labs comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Infinity Bio, Inc.
87%
Antigen Discovery, Inc.
83%
Integral Molecular, Inc.
81%

CDI Labs Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJan 9, 2023
GrantJun 26, 2012
GrantJun 26, 2012
GrantDec 1, 2010

Key People

Founding team and executive leadership

Barney Saunders

CEO

Executive Team

John Corliss

Consulting CFO

Executive Team

Ignacio Pino

Co-counder And COO

Executive Team

CDI Labs Investors

Notable investors and investment history

CDI Labs investors
InvestorRounds
NIH RADxGrant
National Institutes of Health (NIH)STTR Grant, Grant
BroadOak Capital PartnersVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 69% MoM, reaching 15.4K.

  • Sep 29, 2025

    Added Nakliyelojistik, a biotechnology/diagnostics startup, as a customer.

CDI Labs Filings

Explore SEC and related filing metadata, where available.

CDI Labs filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about CDI Labs's valuation, stock price, and market status.

Is CDI Labs a public or private company?

CDI Labs is a private company.

What is the current stock price of CDI Labs?

CDI Labs is a private company, so its shares have no public market price. Caplight tracks CDI Labs's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is CDI Labs worth (valuation)?

Valuation information for CDI Labs is not publicly available.

Can I buy CDI Labs stock?

CDI Labs shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was CDI Labs's last funding round?

CDI Labs's most recent funding round was VC Round on January 9, 2023.

Who are the main investors in CDI Labs?

Key investors in CDI Labs include National Institutes of Health (NIH), BroadOak Capital Partners.

Will CDI Labs IPO soon?

No public IPO plans have been announced for CDI Labs.

How can I track CDI Labs secondary market activity?

Caplight tracks bids, offers, and trades in CDI Labs's shares on secondary markets.

Firmographic Details

HeadquartersMayagüez, Puerto Rico
Employee Range30
Year Founded2008
Last FundingJan 9, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?